Apellis Pharmaceuticals Inc (APLS) — Capital Reinvestment Ratio
Latest as of September 2025:
0.00x
Apellis Pharmaceuticals Inc (APLS) has a Capital Reinvestment Ratio of 0.00x as of September 2025, meaning it reinvests 0% of its operating cash flow ($108.47 Million) in capital expenditures ($148.00K). See Apellis Pharmaceuticals Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$108.47 Million
USD
Capital Expenditures
$148.00K
USD
Data as of
Sep 2025
Most recent filing
Apellis Pharmaceuticals Inc Capital Reinvestment Ratio (2025–2025)
This chart tracks Apellis Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Apellis Pharmaceuticals Inc (2025–2025)
Year-by-year Capital Reinvestment Ratio for Apellis Pharmaceuticals Inc from 2025 to 2025. For live market cap and broader valuation context, see Apellis Pharmaceuticals Inc market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.01x | $45.33 Million | $313.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow